A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
19 06 2020
19 06 2020
Historique:
received:
20
09
2019
accepted:
27
05
2020
entrez:
21
6
2020
pubmed:
21
6
2020
medline:
29
8
2020
Statut:
epublish
Résumé
MLKL is the essential effector of necroptosis, a form of programmed lytic cell death. We have isolated a mouse strain with a single missense mutation, Mlkl
Identifiants
pubmed: 32561755
doi: 10.1038/s41467-020-16819-z
pii: 10.1038/s41467-020-16819-z
pmc: PMC7305203
doi:
Substances chimiques
MLKL protein, human
EC 2.7.-
MLKL protein, mouse
EC 2.7.-
Protein Kinases
EC 2.7.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3150Subventions
Organisme : Wellcome Trust
ID : 076113
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : 19536
Pays : United Kingdom
Organisme : NIAMS NIH HHS
ID : R01 AR059703
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM082729
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : T32 GM008629
Pays : United States
Organisme : Arthritis Research UK
ID : 18797
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 208694/Z/17/Z
Pays : United Kingdom
Références
Newton, K. & Manning, G. Necroptosis and Inflammation. Annu. Rev. Biochem. 85, 743–763 (2016).
pubmed: 26865533
doi: 10.1146/annurev-biochem-060815-014830
Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213–227 (2012).
pubmed: 22265413
pmcid: 22265413
doi: 10.1016/j.cell.2011.11.031
Zhao, J. et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Natl Acad. Sci. USA 109, 5322–5327 (2012).
pubmed: 22421439
doi: 10.1073/pnas.1200012109
Murphy, J. M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443–453 (2013).
pubmed: 24012422
pmcid: 24012422
doi: 10.1016/j.immuni.2013.06.018
Davies, K. A. et al. Distinct pseudokinase domain conformations underlie divergent activation mechanisms among vertebrate MLKL orthologues. Nat Commun. 11, https://doi.org/10.1038/s41467-020-16823-3 (2020).
Samson, A. L. et al. MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. Nat. Commun. 11, https://doi.org/10.1038/s41467-020-16887-1 (2020).
Chen, X. et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res. 24, 105–121 (2014).
pubmed: 24366341
pmcid: 24366341
doi: 10.1038/cr.2013.171
Dondelinger, Y. et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 7, 971–981 (2014).
pubmed: 24813885
pmcid: 24813885
doi: 10.1016/j.celrep.2014.04.026
Hildebrand, J. M. et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc. Natl Acad. Sci. USA 111, 15072–15077 (2014).
pubmed: 25288762
doi: 10.1073/pnas.1408987111
Cai, Z. et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat. Cell Biol. 16, 55–65 (2014).
pubmed: 24316671
pmcid: 24316671
doi: 10.1038/ncb2883
Quarato, G. et al. Sequential engagement of distinct MLKL phosphatidylinositol-binding sites executes necroptosis. Mol. Cell 61, 589–601 (2016).
pubmed: 26853145
pmcid: 4769881
doi: 10.1016/j.molcel.2016.01.011
Tanzer, M. C. et al. Evolutionary divergence of the necroptosis effector MLKL. Cell Death Differ. 23, 1185–1197 (2016).
pubmed: 26868910
pmcid: 26868910
doi: 10.1038/cdd.2015.169
Petrie, E. J. et al. Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis. Nat. Commun. 9, 2422 (2018).
pubmed: 29930286
pmcid: 29930286
doi: 10.1038/s41467-018-04714-7
Gong, Y. N. et al. ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. Cell 169, 286–300 (2017). e216.
pubmed: 28388412
pmcid: 5443414
doi: 10.1016/j.cell.2017.03.020
Yoon, S., Kovalenko, A., Bogdanov, K. & Wallach, D. MLKL, the protein that mediates necroptosis, also regulates endosomal trafficking and extracellular vesicle generation. Immunity 47, 51–65.e57 (2017).
pubmed: 28666573
doi: 10.1016/j.immuni.2017.06.001
Zargarian, S. et al. Phosphatidylserine externalization, “necroptotic bodies” release, and phagocytosis during necroptosis. PLoS Biol. 15, e2002711 (2017).
pubmed: 28650960
pmcid: 5501695
doi: 10.1371/journal.pbio.2002711
Fan, W. et al. Flotillin-mediated endocytosis and ALIX-syntenin-1-mediated exocytosis protect the cell membrane from damage caused by necroptosis. Sci. Signal 12, eaaw3423 (2019).
Wu, J. et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res. 23, 994–1006 (2013).
pubmed: 23835476
pmcid: 3731568
doi: 10.1038/cr.2013.91
Yeh, W. C. et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279, 1954–1958 (1998).
pubmed: 9506948
doi: 10.1126/science.279.5358.1954
Varfolomeev, E. E. et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9, 267–276 (1998).
pubmed: 9729047
doi: 10.1016/S1074-7613(00)80609-3
Kelliher, M. A. et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8, 297–303 (1998).
pubmed: 9529147
doi: 10.1016/S1074-7613(00)80535-X
Zhang, H. et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 471, 373–376 (2011).
pubmed: 21368761
pmcid: 3072026
doi: 10.1038/nature09878
Rickard, J. A. et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 157, 1175–1188 (2014).
pubmed: 24813849
pmcid: 24813849
doi: 10.1016/j.cell.2014.04.019
Dillon, C. P. et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 157, 1189–1202 (2014).
pubmed: 24813850
pmcid: 4068710
doi: 10.1016/j.cell.2014.04.018
Kaiser, W. J. et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc. Natl Acad. Sci. USA 111, 7753–7758 (2014).
pubmed: 24821786
doi: 10.1073/pnas.1401857111
Newton, K., Harris, A. W., Bath, M. L., Smith, K. G. & Strasser, A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 17, 706–718 (1998).
pubmed: 9450996
pmcid: 1170420
doi: 10.1093/emboj/17.3.706
Kang, T. B. et al. Caspase-8 serves both apoptotic and nonapoptotic roles. J. Immunol. 173, 2976–2984 (2004).
pubmed: 15322156
doi: 10.4049/jimmunol.173.5.2976
Kaiser, W. J. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368-+ (2011).
pubmed: 21368762
pmcid: 3060292
doi: 10.1038/nature09857
Oberst, A. et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471, 363–367 (2011).
pubmed: 21368763
pmcid: 3077893
doi: 10.1038/nature09852
Alvarez-Diaz, S. et al. The pseudokinase MLKL and the kinase RIPK3 have distinct roles in autoimmune disease caused by loss of death-receptor-induced apoptosis. Immunity 45, 513–526 (2016).
pubmed: 27523270
pmcid: 5040700
doi: 10.1016/j.immuni.2016.07.016
Rickard, J. A. et al. TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. Elife 3, e03464 (2014).
Dannappel, M. et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 513, 90–94 (2014).
pubmed: 25132550
pmcid: 4206266
doi: 10.1038/nature13608
Hockendorf, U. et al. RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell 30, 75–91 (2016).
pubmed: 27411587
doi: 10.1016/j.ccell.2016.06.002
Newton, K. et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ. 23, 1565–1576 (2016).
pubmed: 27177019
pmcid: 5072432
doi: 10.1038/cdd.2016.46
Anderton, H., Rickard, J. A., Varigos, G. A., Lalaoui, N. & Silke, J. Inhibitor of apoptosis proteins (IAPs) limit RIPK1-mediated skin inflammation. J. Invest. Dermatol 137, 2371–2379 (2017).
pubmed: 28647349
doi: 10.1016/j.jid.2017.05.031
Lalaoui, N. & Brumatti, G. Relevance of necroptosis in cancer. Immunol. Cell Biol. 95, 137–145 (2017).
pubmed: 27922620
doi: 10.1038/icb.2016.120
Liu, X. et al. Key roles of necroptotic factors in promoting tumor growth. Oncotarget 7, 22219–22233 (2016).
pubmed: 26959742
pmcid: 5008357
doi: 10.18632/oncotarget.7924
Faergeman, S. L. et al. A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. Cell Death Dis. 11, 303 (2020).
pubmed: 32358523
pmcid: 7195448
doi: 10.1038/s41419-020-2494-0
Wang, B. et al. A rare variant in MLKL confers susceptibility to ApoE varepsilon4-negative Alzheimer’s disease in Hong Kong Chinese population. Neurobiol. Aging 68, 160 e161–160 e167 (2018).
doi: 10.1016/j.neurobiolaging.2018.03.006
Kauppi, M. et al. Point mutation in the gene encoding p300 suppresses thrombocytopenia in Mpl
pubmed: 18684867
pmcid: 2569170
doi: 10.1182/blood-2007-10-119677
Moriwaki, K. & Chan, F. K. Regulation of RIPK3- and RHIM-dependent necroptosis by the proteasome. J. Biol. Chem. 291, 5948–5959 (2016).
pubmed: 26786097
pmcid: 4786728
doi: 10.1074/jbc.M115.700997
Thapa, R. J. et al. Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc. Natl Acad. Sci. USA 110, E3109–E3118 (2013).
pubmed: 23898178
doi: 10.1073/pnas.1301218110
Rodriguez, D. A. et al. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ. 23, 76–88 (2016).
pubmed: 26024392
doi: 10.1038/cdd.2015.70
Tanzer, M. C. et al. Combination of IAP antagonist and IFNgamma activates novel caspase-10- and RIPK1-dependent cell death pathways. Cell Death Differ. 24, 481–491 (2017).
pubmed: 28106882
pmcid: 5344208
doi: 10.1038/cdd.2016.147
Kuida, K. et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267, 2000–2003 (1995).
pubmed: 7535475
doi: 10.1126/science.7535475
Li, P. et al. Mice deficient in Il-1-beta-converting enzyme are defective in production of mature Il-1-beta and resistant to endotoxic-shock. Cell 80, 401–411 (1995).
pubmed: 7859282
doi: 10.1016/0092-8674(95)90490-5
Conos, S. A. et al. Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proc. Natl Acad. Sci. USA 114, E961–E969 (2017).
pubmed: 28096356
doi: 10.1073/pnas.1613305114
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
pubmed: 5018207
pmcid: 5018207
doi: 10.1038/nature19057
Arnez, K. H. et al. Analysis of the N-terminal region of human MLKL, as well as two distinct MLKL isoforms, reveals new insights into necroptotic cell death. Biosci. Rep. 36, e00291 (2015).
pubmed: 26704887
doi: 10.1042/BSR20150246
Jacobsen, A. V. et al. HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death. Cell Death Dis. 7, e2051 (2016).
pubmed: 26775703
pmcid: 4816171
doi: 10.1038/cddis.2015.386
Bigenzahn, J. W. et al. An inducible retroviral expression system for tandem affinity purification mass-spectrometry-based proteomics identifies mixed lineage kinase domain-like protein (MLKL) as an heat shock protein 90 (HSP90) client. Mol. Cell Proteom. 15, 1139–1150 (2016).
doi: 10.1074/mcp.O115.055350
Zhao, X. M. et al. Hsp90 modulates the stability of MLKL and is required for TNF-induced necroptosis. Cell Death Dis. 7, e2089 (2016).
pubmed: 26866270
pmcid: 4849146
doi: 10.1038/cddis.2015.390
Sim, N. L. et al. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 40, W452–W457 (2012).
pubmed: 22689647
pmcid: 3394338
doi: 10.1093/nar/gks539
Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. Chapter 7, Unit7 20 (2013).
pubmed: 23315928
Dovey, C. M. et al. MLKL requires the inositol phosphate code to execute necroptosis. Mol. Cell 70, 936–948 (2018). e937.
pubmed: 29883610
pmcid: 5994928
doi: 10.1016/j.molcel.2018.05.010
Su, L. J. et al. A plug release mechanism for membrane permeation by MLKL. Structure 22, 1489–1500 (2014).
pubmed: 25220470
pmcid: 4192069
doi: 10.1016/j.str.2014.07.014
Petrie, E. J. et al. Identification of MLKL membrane translocation as a checkpoint in necroptotic cell death using monobodies. Proc. Natl Acad. Sci. USA 117, 8468–8475 (2020).
pubmed: 32234780
doi: 10.1073/pnas.1919960117
Zhang, Y. et al. Receptor-interacting protein kinase 3 promotes platelet activation and thrombosis. Proc. Natl Acad. Sci. USA 114, 2964–2969 (2017).
pubmed: 28242694
doi: 10.1073/pnas.1610963114
Florean, C., Song, S., Dicato, M. & Diederich, M. Redox biology of regulated cell death in cancer: a focus on necroptosis and ferroptosis. Free Radic. Biol. Med 134, 177–189 (2019).
pubmed: 30639617
doi: 10.1016/j.freeradbiomed.2019.01.008
Gutierrez-Arcelus, M., Rich, S. S. & Raychaudhuri, S. Autoimmune diseases - connecting risk alleles with molecular traits of the immune system. Nat. Rev. Genet. 17, 160–174 (2016).
pubmed: 26907721
pmcid: 4896831
doi: 10.1038/nrg.2015.33
Ramos, P. S., Shedlock, A. M. & Langefeld, C. D. Genetics of autoimmune diseases: insights from population genetics. J. Hum. Genet. 60, 657–664 (2015).
pubmed: 26223182
pmcid: 4660050
doi: 10.1038/jhg.2015.94
Karlsson, E. K., Kwiatkowski, D. P. & Sabeti, P. C. Natural selection and infectious disease in human populations. Nat. Rev. Genet. 15, 379–393 (2014).
pubmed: 24776769
pmcid: 4912034
doi: 10.1038/nrg3734
Newton, K., Sun, X. & Dixit, V. M. Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol. Cell Biol. 24, 1464–1469 (2004).
pubmed: 14749364
pmcid: 344190
doi: 10.1128/MCB.24.4.1464-1469.2004
Beisner, D. R., Ch’en, I. L., Kolla, R. V., Hoffmann, A. & Hedrick, S. M. Cutting edge: innate immunity conferred by B cells is regulated by caspase-8. J. Immunol. 175, 3469–3473 (2005).
pubmed: 16148088
doi: 10.4049/jimmunol.175.6.3469
Hwang, S. Y. et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl Acad. Sci. USA 92, 11284–11288 (1995).
pubmed: 7479980
doi: 10.1073/pnas.92.24.11284
Adachi, O. et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9, 143–150 (1998).
pubmed: 9697844
doi: 10.1016/S1074-7613(00)80596-8
Peschon, J. J. et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160, 943–952 (1998).
pubmed: 9551933
Wang, H. Y. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910–918 (2013).
pubmed: 3969854
pmcid: 3969854
doi: 10.1016/j.cell.2013.04.025
Etemadi, N. et al. Lymphotoxin alpha induces apoptosis, necroptosis and inflammatory signals with the same potency as tumour necrosis factor. FEBS J. 280, 5283–5297 (2013).
pubmed: 23815148
doi: 10.1111/febs.12419
Brumatti, G. et al. HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. Oncotarget 4, 1933–1947 (2013).
pubmed: 24177192
pmcid: 3875760
doi: 10.18632/oncotarget.1306
Stafford, C. A. et al. IAPs regulate distinct innate immune pathways to co-ordinate the response to bacterial peptidoglycans. Cell Rep. 22, 1496–1508 (2018).
pubmed: 29425505
doi: 10.1016/j.celrep.2018.01.024
Murai, S. et al. A FRET biosensor for necroptosis uncovers two different modes of the release of DAMPs. Nat. Commun. 9, 4457 (2018).
pubmed: 30367066
pmcid: 6203740
doi: 10.1038/s41467-018-06985-6
Cox, A. J. et al. Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO). PLoS ONE 12, e0169687 (2017).
pubmed: 28301468
pmcid: 5354242
doi: 10.1371/journal.pone.0169687
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199
pmcid: 20644199
doi: 10.1101/gr.107524.110
Genomes Project, C. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
doi: 10.1038/nature15393
Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80–92 (2012).
doi: 10.4161/fly.19695
Liu, X., Wu, C., Li, C. & Boerwinkle, E. dbNSFP v3.0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum. Mutat. 37, 235–241 (2016).
pubmed: 26555599
pmcid: 4752381
doi: 10.1002/humu.22932
Wang, C. et al. Ancestry estimation and control of population stratification for sequence-based association studies. Nat. Genet. 46, 409–415 (2014).
pubmed: 24633160
pmcid: 4084909
doi: 10.1038/ng.2924
Cox, A. J. et al. In trans variant calling reveals enrichment for compound heterozygous variants in genes involved in neuronal development and growth. Genet. Res. 101, e8 (2019).
doi: 10.1017/S0016672319000065
Reveille, J. D. et al. HLA class I and II alleles in susceptibility to ankylosing spondylitis. Ann. Rheum. Dis. 78, 66–73 (2019).
pubmed: 30341055
doi: 10.1136/annrheumdis-2018-213779
Blum, S. et al. Genome-wide association study in Guillain-Barre syndrome. J. Neuroimmunol. 323, 109–114 (2018).
pubmed: 30196823
doi: 10.1016/j.jneuroim.2018.07.016
Oguro, H., Ding, L. & Morrison, S. J. SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell 13, 102–116 (2013).
pubmed: 23827712
pmcid: 3736853
doi: 10.1016/j.stem.2013.05.014